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A B S T R A C T
Because it primarily affects the poor in undeveloped parts of the world where medical care is often inadequate and in-
sufficient, envenomation is considered a neglected public health issue, despite the existence of antivenom therapy for
more than a century. This article provides an overview of the epidemiological situation for important venomous animals, to-
gether with achievements in the production, control, technological progress and safety of antivenoms since their discovery.
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Introduction
Antivenoms fall into the group of animal immunosera
for human use. Depending on their manufacturing pro-
cess, they can contain whole antibodies (immunoglobu-
lins) or parts of antibodies, Fab/F(ab')2 fragments, spe-
cific for antigens of clinical importance, in this case
venoms. Animal immunosera are used, in addition to
antivenoms, as antitoxins, antisera against bacterial and
viral disease causing agents, and as antilymphocytic im-
munoglobulins for induced immunosuppression. In addi-
tion to antivenoms, the majority of topics addressed by
this paper, such as aspects of production, control and
safety of use, are also applicable to other medicinal prod-
ucts from this group. The significance of antivenom is its
efficacy in what are commonly life-threatening situa-
tions that primarily threaten large populations of people
in undeveloped areas of the world. In many of these ar-
eas, medical assistance is often inaccessible following en-
venomation. Issues in the production, control and use of
antivenoms, such as product purification, potency / activ-
ity assessment, standardization, serious side effects due
to oversensitivity to the heterologous components of ani-
mal blood, arose soon after their discovery, and many
have not yet been fully resolved today. Alongside other
factors, including those of an economic nature, such as
rising costs of production of antivenom fallowing mod-
ernization and quality control standards, logistical issues
in the distribution and maintenance of a cold chain,
which are virtually impossible to avoid in the most threa-
tened and impoverished areas where the competent
authorities either do not recognize, pay little attention,
or are unable to resolve the existing situation as a serious
public health problem, production at the global level re-
mains unprofitable. As such, the number of manufactur-
ers of this group of medicines is constantly declining1, re-
sulting in poor accessibility of this life saving product.
There are only a handful of producers, and they are often
not able to meet the increasing quality requirements pre-
scribed by pharmacopoeia, guidelines and other regula-
tory requirements and requirements of good manufac-
turing practice. Competent authorities, on the other
hand, are obliged to monitor and control the implemen-
tation of technological progress in the production and
improvement of the increasingly strict and demanding
quality requirements with regard to maximum drug sa-
fety and efficacy. Global initiatives aimed at increasing
and improving production and availability of antivenoms
where they are most needed have been approved by
many, but are primarily under the support and manage-
ment of the World Health Organization (WHO). This pa-
per provides an overview of the epidemiological situation
for the most significant and most common venomous ani-
mals, and summarizes the results of studies relating to
the production, control, technological progress and safe
use of antivenoms, from their discovery to the present day.
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History
Back in 1877, Fornara protected a dog after inocula-
tions of toad skin secretions and that was the first official
report of successfully performed immunization by re-
peated injections2. Similar experiment was performed in
1887 by Sewall who demonstrated that by applying small
but increasing doses of rattlesnake venom, it was possi-
ble to expose pigeons to doses of the venom more than
seven times higher than the lethal dose, without any ob-
vious effects3. Then in 1892, Kaufmann succeeded in re-
producing Sewall's experiment using Vipera aspis venom
on dogs4. This laid the foundation for the procedure of
immunizing animals for the purpose of active production
of specific antibodies. Not long passed until the practical
application of this discovery was implemented, i.e. the
application of serum to other, non-immunized animals
exposed to venom for therapeutic purposes. Already by
1890, Emil von Behring and Shibasuro Kitasato pub-
lished a paper on the first antitoxin against tetanus.
Behring’s continued research on the development of an-
titoxins against diphtheria brought him the Nobel Prize
for Physiology in 19015. These and similar discoveries
launched a series of applicable studies in which the im-
munization of animals was used for the production of
specific antibodies for passive immunization or sero-
therapy. Soon after, in 1984, Phisalix and Bertrand dem-
onstrated antitoxic activity of the blood of animals im-
munised against Vipera aspis venom using heat – detoxi-
fied venom6. In 1895, Léon Charles Albert Calmette (12
July 1863 – 29 October 1933), a French physician, bacte-
riologist and immunologist, prepared commercial antive-
nom against the venom of the Indian cobra (Naja naja),
obtained through immunization of horses7. Another im-
portant discovery that contributed to development of
immunotherapy was development of toxoids i.e. formal-
dehyde detoxication method by Gaston Ramon in 19248.
Today, more than a century after the discovery of antive-
nom, the most significant research and discoveries are in
the field of pharmacokinetics. These have aided in under-
standing immunotherapy, and in the procedures of puri-
fication, which has largely contributed to the safe use of
antivenoms6.
All attempts to date in discovering, and the discovery
of other potential types of medicines for therapy or pro-
phylaxis, such as the use of specific peptides as vaccines
or other forms of immunization against animal venom,
have not yet been applied9. The main reason for the fail-
ure in the development of toxin-targeted therapy is the
complex composition of venom, which contains hundreds
of functionally different proteins which are difficult to
purify and characterize. Some groups of authors have
also worked on procedures to detoxify venom and apply
the toxin as an agent that would cause a reaction of the
immune system, thereby providing active protection10,11.
According to recent data, thanks to the use of modern
bioinformatic technology, promising results have been
achieved in the synthesis of multi-epitope DNA immuno-
gens, used to obtain serum specific for the toxin in ques-
tion and all its isomeric forms.12 But for the time being,
antivenoms are produced in a similar manner as a century
ago, though with much more modern technology. And
still, these are the only effective method of specific ther-
apy following a bite or sting from a venomous animal.
Venomous Animals – Epidemiology
Antisera are most commonly used against snake and
spider bites and scorpion stings. There are about 600 spe-
cies of venomous snakes in the world13. Though they are
found in different parts of the world, the majority inhabit
the tropical equatorial regions. Therefore, the incidence
of snake bites and the consequential bodily harm or
death is tied to those snake species inhabiting, for the
most part, undeveloped parts of the world. An accurate
number of cases of snake bites and their consequences is
not known and is very difficult to determine because of a
lack of reliable statistical data14, as hospitals are not
commonly visited and traditional home treatment is of-
ten used instead15,16. It can be assumed that about 2.5
million people are envenomed by snakes each year14, and
of these 125,000 will die13. Research of J.P. Chippaux
shows that although we are not at dispose of precise epi-
demiological data, many areas of the world, especially
Asia and Africa are seriously endangered. For example,
this research showed that there is around 1 million snake
bites every year in Africa, involving 500,000 envenoma-
tions, of which approximately 20,000 ends fatally. Only
about 10,000 of mentioned cases are reported by health
services14. Also a good example of the extent of threat to
human health and life can be also seen in India, where
250,000 people are bit each year, and of these about
50,000 people die13. Most recent and comprehensive re-
search showed that globally, each year, at least 421,000
envenomings occur resulting with at least 20,000 deaths,
but this figures could be as high as 1,841,000 enveno-
mings and 94,000 deaths17. Of the fourteen species of
snake found in Croatia, only two are venomous: the nose
horned viper (Vipera ammodytes) and the adder (Vipera
berus)18. According to data from Split Clinical Hospital, a
total of 389 victims of bites from the nose-horned viper
were admitted for treatment over a sixteen year period
(1980–1996)19.
Even if the snake bite does not result in death, it can
still have serious consequences, primarily due to the lack
of treatment or treatment received too late. Serious in-
validity (dysfunction or loss of limbs) or diseases such as
kidney failure, osteomyelitis with malignant transforma-
tions, intracranial bleeding, thromboses and the like can
result13.
Other significant animal species are scorpions. Of the
some 1500 species of scorpion, about 30 species are
harmful to humans, as they produce venom in sufficient
quantities to cause systematic organ failure or death.
There is a significant difference in incidence and severity
of scorpion envenomation in different areas of the world,
depending on species prevalence. The most endangered
areas in wich we can find the most venomous species are
some parts of Africa, Near and Middle east, South India,
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Mexico and South Latin America. There are also difficul-
ties in estimation of incidents due to same reason as in
the case of snake bites, but mortality data are better
known. Some attempts for better control mechanism, in-
cluding improvement of case recording, first resulted
with the »increase« of incidence showing that existing
epidemiological data for scorpionism only partially re-
flect real status and that further study is needed for
more realistic data 20–22. In Mexico for example, scorpion
stings are among the leading public health issues, with
more than 250,000 stings recorded per year and hun-
dreds of deaths ensuing23. At the global level, the annual
number of scorpion stings exceeds 1.2 million leading to
more than 3250 deaths20. The global data indicate that
despite of geographical limitation, scorpionism is public
health concern.
There are about 200 species of spider worldwide that
produce venom that can cause serious harm to humans
after a bite. Epidemiologically, it is difficult to pinpoint
the number of cases due to difficulties in obtaining a di-
agnosis as it is not uncommon for the patient to be un-
aware of the spider bite24. The most important venomous
species are the widow spiders (Latrodectus spp.), recluse
spiders (Loxosceles spp.), funnel-web spiders in Australia
(Atrax and Hadronyche spp.) and the Brazilian wander-
ing spider (Phoneutria spp.)25. The black widow Latro-
dectus mactans tredecimguttatus is the most venomous
spider in the Croatian coastal region. Since 1948. till the
end of 1980s, Mareti} studied intensively Latrodectus spp
ant their toxin26–28 and participated in developement of
the first european anti-latrodectus serum in 1951. Thanks
to health care education, which has increased the ability
of the locals to recognize the black widow in its habitat,
the incidence of latrodectism in Croatia is relatively
low29. In the Zadar region, which is the primary locality
of this spider species in Croatia, a total of 30 cases of
black widow bites were reported from 1998 to 200630.
As it can be seen from presented, epidemiological data
like incidence and severity of envenomations, are not
easy to obtain, but aiming to get more precise data is cru-




The first step in production is the collection of venom,
which represents the antigen for immunization of ani-
mals whose serum is then used to produce the antive-
nom. Snake venom can be collected mechanically by ap-
plying pressure to the venom gland, i.e. active milking,
by hand or using a specialized apparatus, or by elec-
tro-stimulation of the muscles surrounding the gland4.
Venom is also collected from spiders and scorpions by
mechanical or electrical provocation, in which the animal
bites/stings the provocation material (e.g. a tube) and in-
jects its venom into it31.
The venom is dried in an dessicator using accelerators
or by lyophilisation or freeze-drying, which gives crystal-
lized or powdered venom which can be held at refriger-
ated temperatures for many years32,33.
Considering that the strength of the venom is reduced
after the first collection, establishment of the proper col-
lection interval is essential in order to achieve the immu-
nization of the animal with venom of approximately
equal strength. This facilitates product standardization,
which is an important objective. According to some data,
a period of four weeks between collections is sufficient to
ensure venom of equivalent strength4, however, this needs
to be established on a case by case basis, as it is depend-
ent on the type of animal and venom, and on many other
factors.
The composition of venom is exceptionally complex
and contains many complex molecules such as proteins,
enzymes and peptides, as well as many smaller mole-
cules. This demands the use of very sensitive techniques
to separate the antigens from the remaining compo-
nents. These methods must also be adapted to the large
variations not only in the composition of various venoms,
but also in the size of the venom sample that can be ob-
tained, given the type of animal producing it34.
Variations of venoms are present at many levels:
interfamily, intergenus, interspecies / subspecies, intra-
specific, geographical, seasonal, diet / habitat, age and
sex variations35.
In compliance with the European pharmacopeia36 and
the EMEA guidelines37, immunization antigens must be
identified, characterised using chemical and biological
methods and must be free extraneous agents, especially
virus contaminants. Following this, the animal is immu-
nized using an increasing dose of the venom. The animal
of choice is the horse, primarily due to the fact that it can
give the largest quantity of serum. A litre of horse serum
can give 100 mL of snake antivenom. Horse plasma can
be taken once every four weeks, and the animal can be
used for this purpose for about six years38. Other animals
are also used, such as sheep, goats, donkeys and rabbits.
In recent years, research has shown that antibodies ob-
tained from the yolks of eggs of hens immunized with
snake venom have successfully neutralized the pharma-
cological effects of the snake venom39,40, however their
safety and efficacy required further study.
After a period in which the immune system produces
the specific immunoglobulins in sufficient quantities, the
next step is the sterile collection of plasma, primarily
through the procedure of plasmapheresis. In this pro-
cess, the plasma is separated from other blood cell ele-
ments, which are then returned to the animal’s circula-
tory system. The plasma is stored at a temperature of
–20°C or lower until further use.
After the discovery of the principle of serotherapy at
the end of the 19th century, humans were treated with
unprocessed and unpurified immune serums. Their use
resulted in numerous and, not uncommonly, fatal reac-
tions due to a hypersensitivity to proteins, particularly
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albumin. It was considered that these, and not globulin,
were the most responsible for the side effects. According
to the literature on immunosera from the early 20th cen-
tury, it could be concluded that these sera were often as
dangerous as the venoms themselves41. This led to a
number of important advancements in production, par-
ticularly the process of purification, aimed at obtaining
an effective, but safe antiserum. Today, the majority of
manufacturers use methods that isolate and concentrate
immunoglobulins or their active fragments yielded with
enzyme digestion on the basis of salt precipitation, proce-
dure published by Pope 193942. If these are medicinal
products containing the whole immunoglobulin G, any
undesired proteins could be removed through precipita-
tion using caprylic acid (described first time by Chauntin
and Curnish in 196043) and ultrafiltration44,45. In the use
of active fragments, fragmentation is achieved through
digestion using proteolitic enzymes. With the activity of
protease (pepsin, papain) at low pHs and temperatures of
20–25°C, the immunoglobulin molecule is split into Fc
(fragment constant) and Fab/F(ab')2 (fragment antigen
binding) fragments42,44.
The Fab/F(ab')2 fragments, which are the bioactive
parts of the molecule with specific binding properties for
a given antigen, are separated from the inactive Fc part
of the molecule. Most manufacturers achieve the separa-
tion of these fragments using sedimentation with salts,
primarily ammonium and potassium sulphate due to
their ability to precipitate globulins, but not albumins.
Efficiency of this procedure can be improved by combina-
tion of caprylic acid and salt precipitation which was
demonstrated in 199046.
This procedure is further followed by heat denatur-
ation at 55°C for ten or more minutes. During this time,
the undesired thermolabile Fc proteins coagulate, and
the thermostable Fab and F(ab')2 remain47. The dena-
tured proteins can be removed by centrifugation and fil-
tration, while the ammonium sulphate is removed from
the sediment by dialysis or ultrafiltration. A small num-
ber of manufacturers, use additional, more sophisticated
purification methods such as ion-exchange and affinity
chromatography48, especially since the adaptation of
firstly developed methods in 1970s49 to an industrial
scale50.
Cromatography methods can be used alone or in com-
bination with precipitation using caprylic acid.51 Aggluti-
nation with aluminium hydroxide gel is an appropriate
method for the removal of lipids. Final product can be in
a liquid form or lyophilised. Longer shelf life is attributed
to lyophilised antivenom which is a great advantage to
this type of pharmaceutical form, considering unfavour-
able climate conditions and poor distribution organiza-
tion in endangered areas. Inappropriate lyophilisation
and inadequate solubility can result with denaturation
and loss of stability and activity. Lyophilisation process
also increases cost of production significantly48. The ma-
jority of commercially available immunoserums are in
liquid form and contain preservatives, primarily phenol,
cresol or thyomersal52,53. Though with today’s advanced
technology and the principles of good manufacturing
practice, the use of preservatives in medicines should be
avoided wherever possible, their presences in immuno-
sera is still accepted, considering funds that would be
necessary to advance the production and secure distribu-
tion of antivenoms.
Critical phases of production and their control
Critical phases of production that can be singled out
are the procedures of enzyme digestion at low pH values,
the procedures of selective heat denaturation and proce-
dures of antivenom purification. The conditions of these
procedures must be strictly controlled in order to obtain
a product of the desired quality. Proteolitic enzymes of
undesirable composition and/or activities, and the differ-
ences in quality among batches can be the cause of inade-
quate breakdown of the immunoglobulin molecule. This
can result in an increased incidence of side effects48.
During digestion, it is necessary to ensure low pH val-
ues. It has been shown that very small differences in pH
values, together with the length of time of the digestion
itself, can have a significant effect on the immunoglobu-
lin fragments and their biological activity53. The activity
of heat in the process of denaturation of undesired pro-
teins, unless controlled appropriately, can result in the
loss of active substance (excessive denaturation) or inap-
propriate product purity (insufficient denaturation). The
concentration of salts that precipitate and settle out the
globulin protein fragments is also an important factor re-
quiring strict control, as it directly impacts product pu-
rity. The purification procedure also removes general im-
purities such as pyrogenic substances, and undesirable
heterologous proteins that cause side effects. It is logical
that the use of specific, purified and concentrated anti-
bodies or their parts (production of plasma with high spe-
cific activity) reduces the total intake of protein taken
with the medication. Therefore manufacturers of these
parts of the production process must carefully validate
and establish both consistency and standardization, par-
ticularly in the sense of activity and purity of the ob-
tained product. This is carried out through quality con-
trol according to the established requirements confirmed
by the competent authority. The majority of these proce-
dures are important for the safe use of antivenoms.
Pharmacokinetics/Pharmocadynamics
Due to differences in the molecular mass of the active
compounds (whole IgG – 150 kDa, F(ab')2 – 100 kDa; Fab
– 50 kDa), different types of antivenom have different
pharmacokinetic properties. The Fab fragments arrive
first into the extravascular space and have the shortest
elimination time through the kidneys. IgG survives for
longer in tissues and is excreted extrarenally. The ad-
sorption and elimination of F(ab')2 fragments is some-
where in between the two previously described types.54
The complexes that result between the active compounds
of antivenom and the venom are not excreted through
the kidney due to their high molecular weight. Com-
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plexes of venom with F(ab')2 fragments have been ob-
served to be excreted from the body slower than free
venom, but faster than the free fragments, which sug-
gests that these complexes are eliminated from the body
by phagocytosis55. Based on test results, F(ab')2 frag-
ments have the best pharmacokinetic properties. For this
reason, and due to the lower incidence of side effects,
which is greatly due to absence of Fc fragments responsi-
ble for complement activation, F(ab')2 fragments are
most commonly used56. Some authors claim that their ef-
ficacy and safety is significantly dependent on the type of
animal used in the production of antivenom. Fab frag-
ments obtained from sheep serum have proved to have
an equal effect as F(ab')2 obtained from horses, though
with a lower incidence of side effects57. However, it has
been proven that the neutralization effect of Fab frag-
ments is transient and that repeated application of the
antivenom is necessary within a few hours. On the other
hand, a single injection of a medication containing F(ab')2
neutralizes venom for several days58. This is due to the
shorter elimination half-life (t ½) of the Fab fragments
(4.3 hours) in comparison to F(ab')2 fragments with a t ½
of 18 hours59. In line with the newest research on pharma-
cokinetics of the venoms themselves, which have shown
that their kinetic profiles vary greatly, it is clear that the
efficacy of the antivenom and the selection of the active
compounds depends greatly on the characteristics of the
venom60. Venoms of snakes from the Viperide family
characteristically contain toxins of high molecular weight.
These are first quickly absorbed but later switches to a
very slow absorption from the site of venom injection.
For that reason, clinical symptoms can reoccur, even af-
ter the level of antivenom in the blood drops61. Venoms of
snakes from the family Elapide and scorpions contain
neurotoxins of low molecular weight which very quickly
and easily enter into tissues and have a high volume of
distribution. Therefore, it would be ideal for the pharma-
cokinetic characteristics of the antivenom to appropri-
ately follow the pharmacokinetic profile of the venom54.
Safe Use of Antivenom
It is most important to focus on safety considering vi-
ral contamination and undesirable effects, i.e. side ef-
fects, of these medications. Both these aspects of safety,
generally in the production of medicinal products, can
best be achieved through product standardization and
ensuring consistency in quality and efficacy of batches.
Consistency control in the sense of quality implies labo-
ratory characterization of batches using a series of vali-
dated procedures for the purpose of proving purity, iden-
tity, the content of immunoglobulin, quantity of aggre-
gates, etc.
Safety considering viral contamination
Due to their biological origin, and even more so due to
the use of biological materials in production, there is an
objective danger that biological medications may contain
causative agents of infectious diseases that are danger-
ous for humans. The best known case is the transfer of
the SV40 virus in a contaminated poliomyelitis vaccine
in the period from 1955 to 1963 from the cells of the mon-
key from which the vaccine was produced62,63. About half
a century later, the virus began to be connected to the eti-
ology of malignant disease64. Therefore, the world and
European guidelines for the production of biological me-
dications, including immunosera of animal origin65,37 sti-
pulate strict quality control testing for viral contamina-
tion, beginning from the production animal and all the
way to the finished medicinal product. Financial reasons
are the main factor for the failure to carry out these pro-
cedures, or to carry them out entirely, in the majority of
manufacturers. Considering that no cases of viral trans-
fer through immunosera have been recorded66, and con-
sidering the fact that individual parts of the production
procedure have exceptionally strong antiviral effects67, it
is usually evaluated and concluded that the benefits from
their use is significantly higher than the risk of contract-
ing a virus. However, bearing in mind the epizooties that
can affect horse breeding, and the zoonosis caused by
equine diseases (i.e. Hendra and West Nile virus) that do
appear68, and in line with the progress in production
technologies and medicinal product control, it is neces-
sary to conduct contemporary evaluation of the viral
safety of antivenoms and conduct appropriate control ac-
cordingly.
Considering that the study of virology of large ani-
mals has not been exhausted, and that animals for the
production of antivenoms cannot be bred as SPF (specific
pathogen free) colonies, it is important to abide by the
proper breeding principles with constant monitoring,
treatment and prevention where needed, in order to
maintain the good health of the animal used for produc-
tion. In order to ensure that these animals are not vec-
tors of disease causing agents, different methodologies
should be used, such as occasional serological testing,
pathological examination, and more to continually moni-
tor their health status. Second, but no less important,
during production it is necessary to use procedures for
the purpose of inactivation and elimination of viruses. In
comparison with medicinal products from human plas-
ma, the majority of medications made from animal plas-
ma have not yet undergone procedures for this intent,
such as solvent-detergent (S/D), pasteurization or nano-
filtration, while their production is largely not validated
with regard to viral safety48. However, the specific parts
of animal immunosera production process disable vi-
ruses by inactivation or facilitate their elimination, con-
tributing to the viral safety of these medicinal products.
In particular, this is the activity of the low pH and
concentration of pepsin required for the appropriate
proteolityc breakdown, and the activity of caprylic acid.
It is necessary to bear in mind that these procedures
were developed earlier, and validated by manufacturers
of human blood and plasma derivatives, and that their
antiviral activity was confirmed for these products69,70.
In the 1980s, it was proven that exposure to low pH
(about 4) greatly contributes to the inactivation and
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elimination of viruses from medications containing hu-
man immunoglobulins71, while later this activity was
confirmed independently and in combination with other
procedures targeted at viral inactivation, i.e. cold ethanol
fractionation72–74. It has been proven that caprylic acid,
used in the purification of immunosera, in combination
with elevated temperatures and low pH values in human
immunoglobulins and solutions of human albumin has
virucidal properties and the ability to inactivate viruses
with a lipid envelope. The inactivation factor was signifi-
cant, at more than 4 log(10) for the most resistant vi-
ruses tested75,76. However, it should be noted that capry-
lic acid has no effect on viruses without an envelope, and
early studies conducted in general for unsaturated fatty
acids showed that the inactivation effect is lower in prod-
ucts containing a high amount of endogenous lipids, such
as whole plasma and unprocessed plasma fractions, as in
the case with the processing of animal antivenoms with
caprylic acid77. Elevated temperature is another factor
that stimulates inactivation through the activity of these
mechanisms. Considering that production of animal im-
munosera to date do not involve temperatures proven to
inactivate viruses, such as pasteurization which is used
for the production of human immunoglobulins, research
was recently carried out on modified production proce-
dures and the processing of horse serum that included
exposure to 60°C temperatures over 10 hours. The re-
sults confirmed viral inactivation efficacy of pasteuriza-
tion, low pH and caprylic acid in equine serum, as it was
already proven for medicines from human blood and
plasma. The same research showed that a combination of
the usual procedures with pasteurization ensures protec-
tion against viruses that can otherwise survive treat-
ment with low pH and caprylic acid solely. As such, the
reduction factor for lipid-enveloped viruses in this proce-
dure was more than 9 log (10), and for those without an
envelope was 4 log (10)78. External contamination of
plasma is prevented during plasma collection using a
closed system of plasmaphoresis. At a workshop of the
WHO held in London in 2001, it was proposed that man-
ufacturers should carry out a pilot-study that would be
considered a standard method and confirmation of vali-
dation in the sense of removal and activation of viruses
during production process standardization.
Burnouf et al., in an article published in the journal
Biologicals in 2004, suggested that validation studies
should be carried out in which known models of viruses
would be used. These would give results that could tell of
the speed and degree of inactivation during planned inac-
tivation phases in the production process. The selection
of the viral model should be discussed by virologists, and
similar studies carried out on human blood and plasma
derivatives should be taken into consideration66.
Undesired effects/ side effects
The most common side effects following antivenom
treatment are immunological reactions to the heterolo-
gous (animal) serum proteins. Individual studies have
shown that antivenoms produced by the immunization of
camels have a smaller incidence of these types of reac-
tions as their ability to activate the complement is weaker.
However, it has also been proven that the antibody titre
in human serum after treatment with camel antivenom
was lower in comparison with titre achieved after appli-
cation of antivenom produced from horses and sheep79,80.
The results of new studies in the use of human mono-
clonal antibodies are promising and could in the future
become an adequate replacement for heterologous ani-
mal serums81,82. Early (direct or delayed) immunological
reactions are caused by the IgE antibodies. These results
with the degranulation of mast cells and basophils and
release of inflammatory factor and histamines, which in
turn leads to a disbalance in the circulatory system with
vasodilation, vascular permeability, smooth muscle spasms
and local inflammation. Consequences can be serious
such as urticaria, oedema, drop in blood pressure and
asthma. In serious cases when the antigen is present
throughout the entire system, anaphylactic shock may
ensue83. Further, there may be immunological reactions
that arise due to activation of the complement.
The causes of complement activation can be Fc frag-
ments of the heterologous antibodies, proteins/protein
aggregates and the formation of immune complexes84.
Following first two causes, it is important to stress that
though a significant difference in the efficacy of medi-
cines containing whole immunoglobulin or their frag-
ments has not been proven85, and data on side effects for
both types of antivenom are controversial, many authors
indicate that purified whole immunoglobulin G cause a
greater number of undesirable effects86–88. Excessive pro-
teins in general and the creation of protein aggregates is
increased following protein digestion at low pH values89,
therefore an effective and validated purification proce-
dure is essential.
Later reactions appearing after 1 to 15 days can be
seen in local or generalized urticaria, fever and arthral-
gia. This reaction is often called serum disease. It is an
immunological reaction of the body to the accumulations
of the antigen/antibody immunocomplex that stimulates
an inflammatory response in the body and activates the
complement90,91. The use of various diagnostic tests to
establish whether the person is sensitive has not proven
to be fully applicable, as even following a negative diag-
nostic test, unexpected side effects have occurred. Emer-
gency medicine physicians at the Faculty of Medicine at
the university hospital at Ribeirão Preto, University of
São Paulo, published their successful results in the pre-
vention of the appearance of side effects through the use
of antihistamines and corticosteroids at the time of appli-
cation of heterologous animal immunosera92. If the diag-
nosis is made on time and the proper treatment is re-
ceived, which also implied good medical conditions, the
consequences and prognosis for side effects to animal se-
rums are good84.
In addition to immunological reactions to animal pro-
teins, non-allergic reactions such as pyrogenic shock is
possible from insufficiently purified serums containing
bacterial endotoxins84,52. Bacterial endotoxins have an
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affinity for binding to proteins and it is necessary to ap-
ply the appropriate procedure for their removal, particu-
larly since classical methods such as ultrafiltration in the
decontamination of water are usually not sufficiently ef-
fective for protein solutions93. This fact is important con-
sidering that the production of antivenoms includes the
procedure of concentrating proteins. This can lead to an
increased concentration of endotoxins. It has also been
shown that due to the concentration of endotoxins in the
precipitate, their concentrations are increased following
the procedure of sedimentation of ammonium sulphate
in comparison with the activity of caprylic acid94. In addi-
tion to fever and general symptoms, in higher concentra-
tions they can induce septic shock95,96.
As can be seen from the work cited in this chapter,
through the implementation of specific production proce-
dures it is possible to reduce the incidence of side effects
to antivenoms. Therefore, it is in the interest of safe use
and the reduction of side effects, to improve production
in the sense of selecting the most appropriate production
procedures, the development of better purification proce-
dures and standardization of the total concentration of
proteins.
Standardization
From the regulatory aspect, the standardization of
the venom, the antivenom itself, procedure and control
procedures is necessary for the estimation and mainte-
nance of quality, efficacy and safety of the antivenom be-
tween batches. However, during research in this field,
numerous difficulties have arising in meeting the high
regulatory criteria.
Research on animal venoms, particularly on snake
venoms, is primarily carried out in order to characterize
the important components of the venom that are respon-
sible for body impairment and death, for the purpose of
finding the most effective treatment strategy. Numerous
papers in this field have resulted in the isolation and
characterisation of many venoms with regard to their
physical and biological properties, and their biological
activities97–104. In recent years, proteomic analysis has
played an important role and proven to be a useful tool in
generating knowledge. In these fields, the name snake
venomics has already emerged for this type of resear-
ch105–107. Research results have proven, though not ex-
plained, the exceptional variability of venoms, including
of course their pharmacological properties, even within
species, depending on geographical areas, age of the ani-
mal and many other factors108–111. This has made at-
tempts to standardize venoms for animal immunization
very difficult, though this standardization would contrib-
ute to the standardization of production of antivenoms
that are not proving to have equal efficacy towards varia-
tions of venoms of the same species112. The reasons for
difficulties in this type of research are very likely the re-
sult of the exceptional composition complexity of the
venom which contains numerous complex molecules, such
as proteins, enzymes and peptides113.
The next very important factor is the testing of the
potency and biological activity using appropriate meth-
ods, by which it is possible to quantitatively express the
neutralization activity of the antivenom on various ef-
fects of the venom, such as death, necrosis, haemorrha-
ging114, neurotoxicity115, coagulopathy116 and the like.
Considering various effects of the venom, there are vari-
ous methods that are used, but the most commonly used
is one recommended by the WHO (and prescribed in the
European Pharmacopoeia) – testing the neutralization of
the lethal effect on mice. In order to standardize these
types of methods, it is necessary to have local reference
preparations of venom and antivenom. However, in 2003,
there was only one standard for snake antivenom in the
world, the 1st International Standard for antivenom for
the Naja and Hemachatus species, produced from equine
serum and established in 196448. In 2006, Fukuda et al.
published a paper on the standardization of the regional
referential standard for the Mamushi snake (Gloydius
blomhoffi), which is used in the area of Japan, Korea and
China117. In addition to the establishment of reference
materials, the problem with testing potency is the use of
animals, due to the more active application and stricter
demands of the 3R principle. Due to its ethical principles,
this is inclined towards the reduction and replacement of
the use of laboratory animals in general, including rou-
tine drug testing. Therefore, many scientific studies have
set out in that direction, setting high standards concern-
ing sensitivity and reproducibility. Good results in the
sense of simplicity, speed and economics, as well as good
reproducibility, were achieved by Pradhan et al., who de-
veloped a method to test the ability of antivenoms to neu-
tralize cobra venom through passive haemagglutination
and the inhibition of haemagglutination118. Immunoas-
says have also proven to have good results in many
studies119,120.
In 2001, Sells et al. published a paper on a potency
testing method using fertilized chicken eggs in the phase
of embryonic insensitivity and they recorded the lethal
effect of venom to embryos. A comparison of this method
with the conventional ED50 method on rodents gave a
strong correlation121.
When defining antivenom potency by determination
of its capability to neutralize venom effect, clear differ-
ence should be made between lethal and other, specific
effects of venom like dermo- and myonecrosis, edema,
hemorrhage and inflammation at the site of the bite, be-
cause neutralisation of these effect does not mean the
neutralisation of lethal effect, which is determined by le-
thal in vivo test in mice.
Stability
Even though appropriate stability testing is regula-
tory requirement and is an important parameter for the
quality of any medicinal product, the issue of stability in
antivenoms is imperative. This is not only due to the fact
that this is a biological medicine containing complex mol-
ecules inclined to change, but also due to the distribution
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and application of these medications in undeveloped re-
gions where inadequate medical conditions of keeping
and storing these medications and the possibility of brea-
king the cold chain are not negligible factors. It is known
that exposure to elevated temperatures stimulate the
formation of protein aggregates. The use of stabilizers
such as sorbitol and phenol could reduce this negative
effect121,122. Studying the effects of the most commonly
used preservatives (phenol and thyomersal) on antivenom
properties have proven that their presence increases the
formation of aggregates and dimers, and that these prep-
arations can lead to activation of the complements in
vitro123, weakening of the interaction between leukocytes
and endotels, and even the increase or cause of the ap-
pearance of certain side effects124. In light of this, the
safety of these auxiliary compounds in these medications
should be re-evaluated.
In comparison to the liquid form, lyophilisation gives
a product that is stable for a longer period of time at
room temperature or elevated temperatures and has an
overall longer expiry period48. However, one should not
neglect the fact that the procedure of lyophilisation in-
creases production costs, requires the use of additional
testing in process controls and quality controls. Decrease
in neutralising potency has also been noted in some cases
following lyophilisation126.
Availability of Antivenom
Despite persistent envenomation problem, as descri-
bed in chapter Venomous Animals –Epidemiology, the
availability and use of antivenom started to decrease in
last few decades of 20th century and this trend still
exist127. For example, although incidence of snake bite
didn’t decrease in Africa, the number of antivenom com-
mercialised before approximately 25 years dropped from
250,000 doses / year to less than 20,000 vials128. The rea-
sons for that are complex. One already mentioned is in-
consistency and lack of precise epidemiological data. In-
creasing costs of improved production technology and
rising quality control standards also have negative effect
on commercialised manufacture of this type of medicinal
product129. Finally, poor organization of health services
and medicines distribution, deficient, inappropriate and
non-standardised treatment protocols are recognised and
not easy solving problems in endangered areas, which
contribute additionally to current situation. Possible so-
lutions require collaboration on international level and
involvement of many structures including manufactur-
ers, state support, sponsoring, local healthcare providers
etc.
Conclusions
By reviewing the current state of production and use
of antivenoms, the conclusions of many authors and the
World Health Organization are confirmed: despite the
fact that envenomation still represents a serious public
health threat in many parts of the world, even though it
is 21st century, it is a widely neglected problem and im-
provements in this area are moderate. The most signifi-
cant problem is the side effects that arise as reactions to
the heterologous proteins. A summary of the results of
numerous studies can lead to the conclusion that work-
ing towards improving the quality of existing prepara-
tions is a goal worth striving for, and that quality in rela-
tion to the type of origin of the product is the most
significant factor in reducing the appearance of unde-
sired effects. Improvement of quality bears a burden of
significant cost rise, placing antivenoms in a group of
very expensive drugs. Price of a single bottle of anti-
venom, together with distribution problems, lack of epi-
demiological data, poor healthcare organization and edu-
cation are the main reasons that these life saving drugs
are not available in proper quantity in countries where
they are needed. Worldwide cooperation among manufac-
turers and regulatory authorities is required in order to
ensure accessibility and the safe and effective use of
antivenoms, particularly in developing countries. Con-
sidering the wide gap between regulatory requirements
and the possibilities and profitability of manufacturing
processes, one must not forget that the final role of both
– the manufacturer and the competent authority is di-
rected at human life protection. Even today, more than
one hundred years since the production of the first
antivenom, its timely application is still the only effective
treatment following envenomation. Antivenoms should
be available to all requiring them, independent of the
standard of the part of the world in which they live.
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STOLJE]E ANTIVENOMA
S A @ E T A K
Iako specifi~na terapija u obliku primjene `ivotinjskih antiseruma postoji vi{e od jednog stolje}a, otrovanja koja su
posljedica ugriza i uboda otrovnih `ivotinja smatraju se zanemarenim problemom javnog zdravstva, budu}i se uglav-
nom doga|aju u siroma{nim i nerazvijenim dijelovima svijeta u kojima je medicinska pomo} i njega neprimjerena i
nedostatna. U ovom ~lanku dan je pregled epidemiolo{ke situacije za va`nije otrovne `ivotinje, dostignu}a u proizvodnji
i kontroli, tehnolo{kom napretku te sigurnosti primjene antivenoma od njihovog otkri}a.
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